In a U.K. study (BARCODE1) reported in The New England Journal of Medicine, McHugh et al found that screening for prostate cancer with a polygenic risk score was more accurate in diagnosis than screening with prostate-specific antigen (PSA) and magnetic resonance imaging (MRI).
Researchers have uncovered that eating walnuts may improve systemic inflammation and reduce the risk for colorectal cancer, according to a recent study published by Moussa et al in Cancer Prevention Research.
A survey study has shown cautious patient support for the use of artificial intelligence (AI) as a second reader in screening mammograms, according to results published in Radiology: Imaging Center.
As reported in The Lancet Oncology by Mateos et al, the final results of the phase III ALCYONE trial showed persistent benefit with the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in transplant-ineligible patients with newly diagnosed multiple myeloma. The primary analysis of the trial showed that D-VMP significantly improved progression-free survival vs VMP in this setting.
In extended follow-up of the phase II LITESPARK-004 trial reported in The Lancet Oncology, Srinivasan et al found that use of the hypoxia-inducible factor-2α inhibitor belzutifan was associated with maintained benefit in patients with von Hippel–Lindau disease–associated renal cell carcinoma.
In late January 2013, while playing with my young son, I noticed my left breast seemed slightly larger than my right breast. Although, at the time, I had no idea this type of swelling is a hallmark of inflammatory breast cancer, a rare and aggressive disease, I immediately made an appointment with...
In a study reported in the Journal of Clinical Oncology, Choong et al found that omission of endocrine therapy in patients with estrogen receptor–low (1%–10% on immunohistochemistry), early-stage breast cancer was not associated with improved survival outcomes. The study used National Cancer...
The Association for Clinical Oncology (ASCO) is working to understand the extent and scope of several recent executive actions. ASCO recognizes the concern and confusion many are currently experiencing and understands that if there are interruptions in care and research, there can be negative...
On April 11, 2025, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma. (See here for details on approval of this combination immunotherapy for colorectal...
Researchers may have identified the bacterial toxin colibactin as a potential factor contributing to the concerning rise in early-onset colorectal cancer, according to a novel study published by Díaz-Gay et al in Nature. The findings demonstrated a substantial enrichment of colibactin-related...
The U.S. Food and Drug Administration (FDA) recently approved the tyrosine kinase inhibitor cabozantinib (Cabometyx) for adult and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors...
Statin use during targeted therapy treatment led to a 61% improvement in the risk of dying of cancer for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to the results of a study published in Blood Advances. The investigators sought to determine the...